Gene polymorphism of cytochrome P450 significantly affects lung cancer susceptibility.
Aged
Case-Control Studies
China
/ ethnology
Cytochrome P-450 Enzyme System
/ genetics
Female
Genetic Association Studies
/ methods
Genetic Predisposition to Disease
Humans
Kaplan-Meier Estimate
Lung Neoplasms
/ ethnology
Male
Middle Aged
Neoplasm Staging
Polymorphism, Single Nucleotide
Prognosis
Sex Factors
Survival Analysis
cytochrome P450 (CYP450)
genetic polymorphism
lung cancer
susceptibility
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
12
04
2019
revised:
26
05
2019
accepted:
02
06
2019
pubmed:
3
7
2019
medline:
15
8
2020
entrez:
3
7
2019
Statut:
ppublish
Résumé
Cytochrome P450 (CYPs) are heme proteins involved in the metabolism of a variety of endogenous and exogenous substances and play an important role in the carcinogenesis mechanisms of environmental and hereditary factors. The objective of this study was to investigate how polymorphisms of CYPs correlate with lung cancer (LC) susceptibility. Six single nucleotide polymorphisms (SNPs) were genotyped in this study. The chi-square test and unconditional logistic regression model were used to evaluate the correlation between SNPs and LC susceptibility. The expressions and survival data of genes in patients with LC were mined using Oncomine and Kaplan-Meier Plotter database. Four SNPs were found to be significantly associated with the risk of LC development (P < 0.05). The most significant correlation was that the A allele and AA genotype of CYP2D6 rs1065852 were associated with increased risk of LC development (adjusted odds ratio [OR] = 1.35, 95% confidence interval [95%CI] = 1.13-1.60, P = 9.04e-4; OR = 1.83, 95%CI = 1.29-2.59, P = 0.001 respectively). Similar association of this variant was also found in the subgroups of male patients, cases in III-IV stages, positive lymph node, squamous cell carcinomas and adenocarcinomas. Whereas rs1065852 was considered as protective factor in females (adjusted OR = 0.33, 95% CI = 0.16-0.70, P = 0.004). In stratified analyses, the association of CYP24A1 rs2762934, CYP24A1 rs6068816, CYP20A1 rs2043449 polymorphism with LC risk appeared stronger in some subgroups. CYP2D6, CYP24A1 and CYP20A1 are overexpressed in some pathological types of LC (P < 0.05), and high levels of CYP2D6 and CYP20A1 indicate poor and good prognosis of LC, respectively. This study revealed that rs1065852, rs2043449, rs2762s934, and rs6068816 of CYPs were associated with LC susceptibility in the Northwestern Chinese Han population; CYP2D6 and CYP20A1 were overexpressed and correlated with prognosis of LC.
Sections du résumé
BACKGROUND
Cytochrome P450 (CYPs) are heme proteins involved in the metabolism of a variety of endogenous and exogenous substances and play an important role in the carcinogenesis mechanisms of environmental and hereditary factors. The objective of this study was to investigate how polymorphisms of CYPs correlate with lung cancer (LC) susceptibility.
METHODS
Six single nucleotide polymorphisms (SNPs) were genotyped in this study. The chi-square test and unconditional logistic regression model were used to evaluate the correlation between SNPs and LC susceptibility. The expressions and survival data of genes in patients with LC were mined using Oncomine and Kaplan-Meier Plotter database.
RESULTS
Four SNPs were found to be significantly associated with the risk of LC development (P < 0.05). The most significant correlation was that the A allele and AA genotype of CYP2D6 rs1065852 were associated with increased risk of LC development (adjusted odds ratio [OR] = 1.35, 95% confidence interval [95%CI] = 1.13-1.60, P = 9.04e-4; OR = 1.83, 95%CI = 1.29-2.59, P = 0.001 respectively). Similar association of this variant was also found in the subgroups of male patients, cases in III-IV stages, positive lymph node, squamous cell carcinomas and adenocarcinomas. Whereas rs1065852 was considered as protective factor in females (adjusted OR = 0.33, 95% CI = 0.16-0.70, P = 0.004). In stratified analyses, the association of CYP24A1 rs2762934, CYP24A1 rs6068816, CYP20A1 rs2043449 polymorphism with LC risk appeared stronger in some subgroups. CYP2D6, CYP24A1 and CYP20A1 are overexpressed in some pathological types of LC (P < 0.05), and high levels of CYP2D6 and CYP20A1 indicate poor and good prognosis of LC, respectively.
CONCLUSION
This study revealed that rs1065852, rs2043449, rs2762s934, and rs6068816 of CYPs were associated with LC susceptibility in the Northwestern Chinese Han population; CYP2D6 and CYP20A1 were overexpressed and correlated with prognosis of LC.
Identifiants
pubmed: 31264381
doi: 10.1002/cam4.2367
pmc: PMC6712450
doi:
Substances chimiques
Cytochrome P-450 Enzyme System
9035-51-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4892-4905Informations de copyright
© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Cancer Res. 2000 Sep 15;60(18):5074-9
pubmed: 11016631
Lancet Oncol. 2011 Apr;12(4):399-408
pubmed: 20951091
Pharmacol Ther. 2013 Apr;138(1):103-41
pubmed: 23333322
Drug Metab Rev. 2007;39(2-3):627-37
pubmed: 17786643
Chem Res Toxicol. 2008 Dec;21(12):2313-23
pubmed: 19548353
Carcinogenesis. 1991 Jul;12(7):1197-201
pubmed: 2070484
Clin Cancer Res. 2007 Jun 15;13(12):3731-7
pubmed: 17575239
Hum Pathol. 2016 Apr;50:101-8
pubmed: 26997443
Lancet. 2015 Oct 10;386(10002):1447-56
pubmed: 26466050
Cell. 2002 Feb 22;108(4):545-56
pubmed: 11909525
CA Cancer J Clin. 2018 Nov;68(6):446-470
pubmed: 30303518
Ann Oncol. 2004 Feb;15(2):236-41
pubmed: 14760115
Allergy. 2011 Nov;66(11):1442-8
pubmed: 21819409
Carcinogenesis. 2008 Jun;29(6):1164-9
pubmed: 18258609
JAMA. 2016 Jan 5;315(1):68-76
pubmed: 26746459
Nature. 2008 Apr 3;452(7187):633-7
pubmed: 18385738
Int J Cancer. 2006 Oct 15;119(8):1819-28
pubmed: 16708384
J Thorac Oncol. 2014 Apr;9(4):473-82
pubmed: 24736069
Recent Results Cancer Res. 2003;164:239-46
pubmed: 12899526
Clin Cancer Res. 2011 Feb 15;17(4):817-26
pubmed: 21169243
Int J Mol Sci. 2016 Sep 22;17(10):
pubmed: 27669215
Lung Cancer. 2001 Feb-Mar;31(2-3):139-48
pubmed: 11165392
J Clin Endocrinol Metab. 1994 Aug;79(2):554-60
pubmed: 8045976
Cancer Epidemiol Biomarkers Prev. 2011 Jun;20(6):1255-8
pubmed: 21527579
Science. 2002 Jun 21;296(5576):2225-9
pubmed: 12029063
JAMA Oncol. 2018 Nov 1;4(11):1553-1568
pubmed: 29860482
Environ Mol Mutagen. 2014 Mar;55(2):134-44
pubmed: 24519899
Anticancer Res. 2013 Feb;33(2):543-51
pubmed: 23393347
Toxicol Sci. 2015 May;145(1):5-15
pubmed: 25911656
RNA. 2016 Sep;22(9):1285-301
pubmed: 27530828
Chem Res Toxicol. 2012 Jul 16;25(7):1316-83
pubmed: 22531028
J Epidemiol. 2000 Sep;10(5):349-60
pubmed: 11059519
Drug Metab Dispos. 2008 Sep;36(9):1930-7
pubmed: 18541694
Lancet. 2002 Oct 12;360(9340):1155-62
pubmed: 12387968
Carcinogenesis. 2014 Nov;35(11):2584-91
pubmed: 25173884
Cancer Med. 2019 Aug;8(10):4892-4905
pubmed: 31264381
Environ Health Prev Med. 2002 May;7(2):47-59
pubmed: 21432264
Br J Cancer. 2015 Jul 28;113(3):524-32
pubmed: 26125444
Curr Drug Metab. 2015;16(10):850-63
pubmed: 26652254
BMC Cancer. 2012 Dec 04;12:568
pubmed: 23207012
Toxicol Appl Pharmacol. 2015 Sep 01;287(2):149-160
pubmed: 26049101
Cancer Res. 1996 Jan 15;56(2):251-3
pubmed: 8542575
World J Gastroenterol. 2017 Jul 28;23(28):5179-5186
pubmed: 28811712
Nat Genet. 2014 Jul;46(7):736-41
pubmed: 24880342
Cancer Res. 2009 Aug 15;69(16):6633-41
pubmed: 19654303
Curr Med Chem. 2009;16(2):232-44
pubmed: 19149574
Arthritis Rheumatol. 2016 Jan;68(1):184-90
pubmed: 26316040
J Thorac Oncol. 2016 Jan;11(1):39-51
pubmed: 26762738
Nat Genet. 2000 Jun;25(2):144-6
pubmed: 10835626
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
J Thorac Oncol. 2018 Jul;13(7):938-945
pubmed: 29626620
Sci Rep. 2017 Oct 30;7(1):14300
pubmed: 29085026
Control Clin Trials. 1998 Dec;19(6):589-601
pubmed: 9875838
Toxicol Sci. 2011 Dec;124(2):261-77
pubmed: 21920951